Inclusion on Group Purchasing Organization
Contracts Can Offer Greater Patient Access
CENTER
VALLEY, Pa., March 28,
2024 /PRNewswire/ -- Olympus, a leading global
medtech company providing innovative solutions for medical and
surgical procedures, announced today a milestone for its iTind™
device with its availability and greater patient access through the
largest healthcare group purchasing organization (GPO) contracts in
the United States.
The iTind procedure is a minimally invasive procedure for the
treatment of benign prostatic hyperplasia (BPH) or enlarged
prostate. The iTind device is now available on 13 GPO contracts in
the U.S.
GPOs exist to help healthcare providers, such as hospitals,
ambulatory surgical centers and nursing homes, save money by
aggregating their purchasing power and standardizing and
streamlining purchasing. The Healthcare Supply Chain Association
estimates nearly all hospitals and a majority of non-acute care
centers in America belong to at least one GPO.1
"The availability of the iTind device through major GPO
contracts marks an important milestone for Olympus," said
Jay Sullivan, Group Vice President,
Enterprise Solutions, Medical Systems Group, Olympus. "Most
importantly, it means greater physician and patient access to a
minimally invasive treatment option for a common urological
condition that does not require medications, permanent implants or
the removal of tissue."
BPH is a common health problem for men over 50 as the risk
increases with age. Symptoms of BPH include frequent urination with
a sense of urgency and a weak urinary stream and excessive
urination at night.2
About the iTind procedure
Evidence shows the iTind procedure is an effective alternative
to pharmaceutical therapy, as well as an alternative to surgeries
and permanent implants, and is proven to relieve symptoms without
affecting sexual and ejaculatory function3,4 or urinary
continence.5
The iTind procedure involves the placement of a temporarily
implanted nitinol device that reshapes the prostatic urethra
without burning or cutting out the prostate. The device can be
placed in an outpatient setting or physician office. It remains in
place for five to seven days while the patient is at home. Upon
removal, patients experience rapid and effective relief of their
symptoms.3,4
Recently published data show that the iTind™ procedure provides
long-lasting relief of more than four years. The long-term study
data demonstrates that the iTind procedure leads to significant and
durable reduction of BPH-related LUTS (lower urinary tract
symptoms) and improved IPSS (International Prostate Symptom Score)
and QoL (Quality of Life) for over 50 months and up to 79 months
(6.6 years) following treatment.6
AUA Guidelines
The iTind procedure has also been included in the American
Urological Association (AUA) clinical practice guideline for
management of LUTS attributed to BPH. The iTind procedure is
reflected in the new procedure category, Temporary Implanted
Prostatic Devices (TIPD).7 The addition of the TIPD
category is based on expert opinion reflecting peer-reviewed
treatment recommendations and research updates.
The iTind procedure may not be for everyone. Please consult with
a doctor to see if the iTind procedure is right for you. As with
any medical procedure, implantation of the iTind device comes with
the possibility of side effects, including pelvic discomfort, blood
in urine, and/or painful or urgent urination. In rare cases, the
iTind device may cause urinary tract infection or a sudden
difficulty to urinate.
More information about the iTind procedure is available at
BPHTherapy.com/iTind.
About Olympus
At Olympus, we are committed to Our Purpose of making people's
lives healthier, safer and more fulfilling. As a global medical
technology company, we partner with healthcare professionals to
provide solutions and services for early detection, diagnosis and
minimally invasive treatment, aiming to improve patient outcomes by
elevating the standard of care in targeted disease states.
For more than 100 years, Olympus has pursued a goal of
contributing to society by producing products designed with the
purpose of delivering optimal outcomes for its customers around the
world.
Olympus Corporation of the Americas, a wholly owned subsidiary
of Olympus Corporation, is headquartered in Center Valley, Pennsylvania, USA, and employs
more than 4,500 employees throughout locations in North and
South America. For more
information, visit olympusamerica.com.
1 Healthcare Supply Chain Association,
supplyassociation.org, Frequently Asked Questions
2 Urology Care Foundation, urologyhealth.org, "Urology
A-Z: Benign Prostatic Hyperplasia (BPH)." Updated September 2023
3 Elterman, D; Alshak, M; Martinez Diaz, S; et al. "An Evaluation of
Sexual Function in the Treatment of Lower Urinary Tract Symptoms
Secondary to Benign Prostatic Hyperplasia in Men Treated with the
Temporarily Implanted Nitinol Device." Journal of Endourology, pub.
December 2022
4 Chughtai, B; Elterman, D; Shore, N; et al. "The iTind
Temporarily Implanted Nitinol Device for the Treatment of Lower
Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A
Multicenter, Randomized, Controlled Trial." Journal of Urology,
pub. July 2021
5 De Nunzio C, Cantiello F, Fiori C, et al. Urinary and
sexual function after treatment with temporary implantable nitinol
device (iTind) in men with LUTS: 6-month interim results of the
MT-06-study. World J Urol. 2021
6 Amparore, D; De Cillis, S; Schulman, C; Kadner, G;
Fiori, C; Porpiglia, F. "Temporary implantable nitinol device for
benign prostatic hyperplasia-related lower urinary tract symptoms:
over 48-month results." [published online ahead of print, 2023 Jun
23]
7 Sandhu, JS; Bixler, BR; Dahm, P; et al.
« Management of lower urinary tract symptoms attributed to
benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023."
Journal of Urology 2023
View original content to download
multimedia:https://www.prnewswire.com/news-releases/olympus-announces-itind-treatment-milestone-with-availability-through-major-gpos-302102871.html
SOURCE Olympus Corporation of the Americas